SG11202004939SA - Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody - Google Patents

Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Info

Publication number
SG11202004939SA
SG11202004939SA SG11202004939SA SG11202004939SA SG11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA SG 11202004939S A SG11202004939S A SG 11202004939SA
Authority
SG
Singapore
Prior art keywords
biomarker
ligand
antibody
treatment
methods
Prior art date
Application number
SG11202004939SA
Other languages
English (en)
Inventor
Peter Peizhi Luo
Guizhong Liu
Fangyong Du
Original Assignee
Adagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adagene Inc filed Critical Adagene Inc
Publication of SG11202004939SA publication Critical patent/SG11202004939SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202004939SA 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody SG11202004939SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/114247 WO2019104716A1 (en) 2017-12-01 2017-12-01 Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
PCT/CN2018/118631 WO2019105468A1 (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Publications (1)

Publication Number Publication Date
SG11202004939SA true SG11202004939SA (en) 2020-06-29

Family

ID=66664325

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004939SA SG11202004939SA (en) 2017-12-01 2018-11-30 Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody

Country Status (8)

Country Link
US (1) US20200377608A1 (https=)
EP (1) EP3717010A4 (https=)
JP (1) JP2021507877A (https=)
CN (1) CN111344014A (https=)
AU (1) AU2018377751A1 (https=)
CA (1) CA3079479A1 (https=)
SG (1) SG11202004939SA (https=)
WO (2) WO2019104716A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
CR20200459A (es) * 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
US20220411523A1 (en) * 2019-11-13 2022-12-29 Hefei Hankemab Biotechnology Co., Ltd Molecule capable of binding to human 4-1bb and its application thereof
WO2021226883A1 (en) * 2020-05-13 2021-11-18 Adagene Ag Compositions and methods for treating cancer submission of sequence listing on ascii text file
TW202200622A (zh) 2020-05-13 2022-01-01 瑞士商天演藥業公司 用於治療癌症之組成物及方法
CN116600805A (zh) * 2020-06-23 2023-08-15 天演药业公司 包含抗cd137抗体的组合疗法
GB202210957D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) * 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US20070253961A1 (en) * 2004-06-09 2007-11-01 Ulsan Industrial Education Foundation Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN1294146C (zh) * 2005-10-17 2007-01-10 山东大学 与t细胞表面共刺激分子cd137结合的多肽及其应用
ES2336873B1 (es) * 2007-11-07 2011-01-24 Proyecto De Biomedicina Cima, S.L. Composicion farmaceutica para el tratamiento de cancer.
EP3082839A4 (en) * 2013-12-20 2017-08-09 National University of Singapore Differentiation therapy with cd137 ligand agonists
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合ｃｄ１３７之抗體治療劑
HRP20201022T1 (hr) * 2015-09-22 2020-10-16 Dingfu Biotarget Co., Ltd Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof

Also Published As

Publication number Publication date
CA3079479A1 (en) 2019-06-06
WO2019105468A8 (en) 2020-05-14
CN111344014A (zh) 2020-06-26
JP2021507877A (ja) 2021-02-25
AU2018377751A1 (en) 2020-07-16
EP3717010A1 (en) 2020-10-07
US20200377608A1 (en) 2020-12-03
EP3717010A4 (en) 2021-09-01
WO2019104716A1 (en) 2019-06-06
WO2019105468A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
SG11202004939SA (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
IL288649A (en) Human antibodies against tau
SG11202000747VA (en) Anti-cd137 antibodies
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
PL3285784T3 (pl) Sposób wytwarzania próbki mikrobioty kałowej
SI3113797T1 (sl) Protitelesa, uporabe in postopki
IL252716A0 (en) Anti-csf1r antibodies for the treatment of pvns
ZA201700824B (en) Carrier molecule for antigens
IL247277A0 (en) Monoclonal antibodies against Ebola
PT3166970T (pt) Anticorpos de ligação a protofibrilas a-beta aperfeiçoados
IL266564A (en) Methods for treating obesity with anti-angptl8 antibodies
PL3178803T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
SG11201701875YA (en) Methods for detecting ovarian cancer
ZA201608777B (en) Method for preparing methyl mercaptan
GB201905146D0 (en) Method for preparing aronatic hydrocarbons
HUE054626T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
HUE063885T2 (hu) Eljárás etén elõállítására
PL3508512T3 (pl) Sposób wytwarzania poliwęglanu
PT3224226T (pt) Processo de preparação de eteno
HK40037607A (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
GB2527129B (en) Method for preparing a ninhydrin reagent
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods
GB201412041D0 (en) Method for preparing a sorbent
GB201409660D0 (en) Method for preparing a sorbent